Homocysteine is an amino acid produced when your body metabolizes methionine from dietary protein. It is an intermediate, not an end product — the body is supposed to clear it quickly. Elevated levels are associated with accelerated cardiovascular disease, cognitive decline, and dementia. It is rarely on standard panels, and the range where most of that risk association sits (9 to 15 μmol/L) falls inside the band labs call normal.
The Verdict
What homocysteine physically measures
Your body clears homocysteine down two routes. The first, remethylation, converts it back into methionine using folate and vitamin B12. The second, transsulfuration, converts it into cysteine using vitamin B6. A third backup route uses betaine.
If any of those cofactors are short, homocysteine accumulates in the blood. That is why the test doubles as a functional readout of B-vitamin status. Serum B12 can look adequate while the pathway is starved at the tissue level; homocysteine catches that case.
Standard range vs optimal range
| Context | Homocysteine | What it means |
|---|---|---|
| Typical lab reference range | Roughly 5–15 μmol/L | Wide, and derived from populations with common marginal B-vitamin status. |
| Optimal | Under 8 μmol/L | Where B-vitamin status is clearly adequate and methylation is running cleanly. |
| Grey zone | 9–14 μmol/L | Inside "normal." This is where most of the observed risk association sits. |
| Moderately elevated | 15–30 μmol/L | Almost always nutritional, renal, or thyroid in origin. Investigate the cause. |
| Markedly elevated | Above 30 μmol/L | Suggests severe B12 deficiency, significant kidney impairment, or an inherited enzyme defect. |
Why the gap matters
Elevated homocysteine damages the vascular endothelium and promotes atherosclerosis in mechanistic studies. In large observational cohorts it tracks with stroke risk, cognitive decline, and rate of brain atrophy. A person sitting at 13 μmol/L gets a clean lab report every year while carrying a correctable deficiency.
The causal picture is contested, and worth setting out plainly. Large randomized B-vitamin trials lowered homocysteine reliably but did not reduce coronary events, though some showed a modest stroke benefit. That result suggests homocysteine is partly a marker of B-vitamin and kidney status rather than a direct cause of coronary disease. It remains worth measuring, because what it flags is fixable.
What raises homocysteine, ranked
| Cause | How often it explains a result | Notes |
|---|---|---|
| Low B12, folate, or B6 status | The most common cause by far | These three vitamins are the direct cofactors for clearing homocysteine. |
| Reduced kidney function | Very common in older adults | The kidneys handle most homocysteine clearance. eGFR decline raises it independently of diet. |
| MTHFR variants (C677T, A1298C) | Common — roughly 10% of people carry two C677T copies | Homozygous C677T cuts enzyme activity by around 70%, and matters most when folate intake is low. |
| Hypothyroidism | Common and fully reversible | Homocysteine often normalizes on its own once thyroid replacement is adequate. |
| Medications | Situational but frequently missed | Metformin and proton pump inhibitors deplete B12. Methotrexate blocks folate directly. |
| Nitrous oxide exposure | Uncommon, occasionally dramatic | Nitrous oxide irreversibly inactivates B12. Recreational use can push homocysteine very high. |
| Smoking, heavy coffee intake, older age, male sex | Additive, modest | Each shifts the number a little. Together they explain part of the population spread. |
The MTHFR connection, in proportion
The MTHFR gene codes for an enzyme that converts folate into its usable methylated form. The C677T variant is common: roughly one in ten people of European ancestry carry two copies, and rates differ by population. Two copies reduce enzyme activity by about 70%; one copy by around 35%.
The important qualifier is that this matters most when folate intake is low. In populations with folic acid food fortification, the homocysteine difference between genotypes narrows considerably. That is why the practical response is the same either way — measure homocysteine, and if it is high, supply methylfolate rather than plain folic acid.
How to lower it
| Intervention | Typical dose | Notes |
|---|---|---|
| Methylfolate (5-MTHF) | 400–1,000 mcg/day | Preferred over folic acid when an MTHFR variant is present or suspected. |
| Methylcobalamin or hydroxocobalamin B12 | 500–1,000 mcg/day oral | Correct B12 first. High-dose folate can mask an untreated B12 deficiency. |
| Pyridoxal-5-phosphate (active B6) | 20–50 mg/day | Do not exceed 100mg/day long term — chronic high-dose B6 causes peripheral neuropathy. |
| Betaine (trimethylglycine) | 1.5–3 g/day | A second clearance pathway. Added when B vitamins alone do not get there. |
| Dietary folate | Leafy greens, lentils, asparagus, avocado | Supports the same pathway. Slower, but it works at ordinary intakes. |
| Treat the underlying driver | Thyroid, kidney, medication review | Where these are the cause, supplementation alone rarely fixes the number. |
One safety rule outranks the others: correct B12 before loading folate. High-dose folate can normalize the blood picture of B12 deficiency while the neurological damage continues underneath. Check B12 — and methylmalonic acid if B12 is borderline — before starting high-dose folate.
How and when to test
- Fast 8–12 hours. A protein-heavy meal raises homocysteine for several hours afterward.
- Confirm the lab chills and separates the sample promptly. This is the single largest source of false elevation.
- Order B12, folate, TSH, and creatinine alongside it. Without those, an elevated result cannot be attributed to a cause.
- Testing once is often enough if the result is comfortably under 8 and nothing changes.
- Re-test 8–12 weeks after starting supplementation, not sooner. The pathway takes weeks to reach a new steady state.
- Re-test after starting metformin or a proton pump inhibitor, since both deplete B12 over months to years.
What it means in combination
- High homocysteine + low-normal B12: functional B12 deficiency. Serum B12 has a wide grey zone; homocysteine and methylmalonic acid resolve it.
- High homocysteine + reduced eGFR: kidney clearance is the likely driver. Supplements will move it only partway.
- High homocysteine + high TSH: treat the thyroid first and re-measure. It often normalizes without any B vitamins.
- High homocysteine + low omega-3 index: a genuinely non-obvious interaction. In a randomized trial of older adults with mild cognitive impairment, B vitamins slowed brain atrophy only in participants who already had good omega-3 status. Correcting both together appears to matter more than correcting either alone.
- High homocysteine + high ApoB or high Lp(a): independent risks stacking. The lipid markers usually deserve treatment priority, since the trial evidence there is far stronger.
When a result warrants seeing a physician
- Homocysteine above 30 μmol/L, which points to severe B12 deficiency, significant kidney impairment, or an inherited enzyme defect.
- Any result above 15 μmol/L that does not fall after 12 weeks of adequate supplementation.
- Elevation alongside numbness, tingling, balance problems, or memory change — a possible B12-related neurological presentation that needs assessment, not a supplement.
- Elevation with a personal or family history of unexplained blood clots, early stroke, or lens dislocation, which can suggest homocystinuria.
- Any elevation in pregnancy or while trying to conceive, given the established folate and neural-tube link.
Frequently Asked Questions
What is a good homocysteine level?
Under 8 μmol/L is the usual optimization target. Standard labs only flag results above roughly 15 μmol/L. The 9–15 band sits inside "normal" and is where most of the observed association with cardiovascular and cognitive risk lives, so a normal flag is not reassurance.
What causes elevated homocysteine?
Ranked by how often each explains a result: insufficient B12, folate, or B6; reduced kidney function; MTHFR gene variants; untreated hypothyroidism; and medications including metformin, proton pump inhibitors, and methotrexate. Smoking, heavy coffee intake, older age, and male sex each add a smaller amount.
How do I lower homocysteine?
Methylated B vitamins are first-line: 400–1,000 mcg of methylfolate, 500–1,000 mcg of B12, and 20–50 mg of active B6. Correct B12 before pushing folate. Betaine at 1.5–3 g/day is added when B vitamins alone fall short. If the cause is thyroid, kidney, or a medication, address that first — supplements will not overcome it.
Does lowering homocysteine actually prevent heart attacks?
This is where the evidence is genuinely mixed and worth stating plainly. Large B-vitamin trials lowered homocysteine substantially but did not reduce heart attacks. Some showed a modest reduction in stroke. So homocysteine may be partly a marker of underlying B-vitamin and kidney status rather than a direct cause of coronary events. It still identifies a correctable deficiency, and correcting it is cheap and safe.
Should I get tested for MTHFR?
Usually not necessary. Homocysteine itself tells you whether the pathway is working, which is the actionable question. Genotyping only tells you about one input. If homocysteine is high, methylated B vitamins are a reasonable empirical response whether or not you know your genotype. Testing MTHFR without measuring homocysteine is the wrong order.
How often should homocysteine be re-tested?
Re-test 8 to 12 weeks after starting supplementation, which is enough time for a stable new level. Most people see the number fall by 20–40% if a nutritional deficiency was the driver. If it barely moves, the cause is more likely kidney function, thyroid, or a medication — and the workup should shift accordingly.